Inflammatory Processes in Drug Discovery - SRI Conference. 22-23 September 2003, Philadelphia, PA, USA.
AstraZeneca R&D, Disease Science Section, Discovery Bioscience Division, Loughborough, Leicestershire, LE11 5RH, UK. martin.braddock@astrazeneca.com
Martin
M
Braddock
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D030801:Animals, Genetically Modified; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016207:Cytokines / Q000378:metabolism; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D040901:Proteomics; D018805:Sepsis / Q000188:drug therapy
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D004791:Enzyme Inhibitors